Analytical solution of two-layer beam taking into account interlayer slip and shear deformation

A mathematical model is proposed and its analytical solution derived for the analysis of the geometrically and materially linear two-layer beams with different material and geometric characteristics of an individual layer. The model takes into account the effect of the transverse shear deformation on displacements in each layer. The analytical study is carried out to evaluate the influence of the transverse shear deformation on the static and kinematic quantities. We study a simply supported two-layer planar beam subjected to the uniformly distributed load. Parametric studies have been performed to investigate the influence of shear by varying material and geometric parameters, such as interlayer slip modulus (K), flexural-to-shear moduli ratios (E/G) and span-to-depth ratios (L/h). The comparison of the results for vertical deflections shows that shear deformations are more important for high slip modulus, for ``short'' beams with small L/h ratios, and beams with high E/G ratios. In these cases, the effect of the shear deformations becomes significant and has to be addressed in design. It also becomes apparent that models, which consider the partial interaction between the layers, should be employed if beams have very flexible connections

Energy expenditure estimation using visual and inertial sensors

© The Institution of Engineering and Technology 2017. Deriving a person's energy expenditure accurately forms the foundation for tracking physical activity levels across many health and lifestyle monitoring tasks. In this study, the authors present a method for estimating calorific expenditure from combined visual and accelerometer sensors by way of an RGB-Depth camera and a wearable inertial sensor. The proposed individual-independent framework fuses information from both modalities which leads to improved estimates beyond the accuracy of single modality and manual metabolic equivalents of task (MET) lookup table based methods. For evaluation, the authors introduce a new dataset called SPHERE_RGBD + Inertial_calorie, for which visual and inertial data are simultaneously obtained with indirect calorimetry ground truth measurements based on gas exchange. Experiments show that the fusion of visual and inertial data reduces the estimation error by 8 and 18% compared with the use of visual only and inertial sensor only, respectively, and by 33% compared with a MET-based approach. The authors conclude from their results that the proposed approach is suitable for home monitoring in a controlled environment

'A habitual disposition to the good': on reason, virtue and realism

Amidst the crisis of instrumental reason, a number of contemporary political philosophers including Jürgen Habermas have sought to rescue the project of a reasonable humanism from the twin threats of religious fundamentalism and secular naturalism. In his recent work, Habermas defends a post-metaphysical politics that aims to protect rationality against encroachment while also accommodating religious faith within the public sphere. This paper contends that Habermas’ post-metaphysical project fails to provide a robust alternative either to the double challenge of secular naturalism and religious fundamentalism or to the ruthless instrumentalism that underpins capitalism. By contrast with Habermas and also with the ‘new realism’ of contemporary political philosophers such as Raymond Geuss or Bernard Williams, realism in the tradition of Plato and Aristotle can defend reason against instrumental rationality and blind belief by integrating it with habit, feeling and even faith. Such metaphysical–political realism can help develop a politics of virtue that goes beyond communitarian thinking by emphasising plural modes of association (not merely ‘community’), substantive ties of sympathy and the importance of pursuing goodness and mutual flourishing

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.